Free Trial

Phio Pharmaceuticals 8/14/2024 Earnings Report

Phio Pharmaceuticals logo
$1.29 -0.02 (-1.53%)
As of 03/28/2025 04:00 PM Eastern

Phio Pharmaceuticals EPS Results

Actual EPS
-$3.62
Consensus EPS
-$4.59
Beat/Miss
Beat by +$0.97
One Year Ago EPS
N/A

Phio Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Phio Pharmaceuticals Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

Remove Ads

Phio Pharmaceuticals Earnings Headlines

Phio Pharmaceuticals expands board with new director
Phio Pharmaceuticals Appoints David Deming to Board
Trump’s Great Society
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Phio Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Phio Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phio Pharmaceuticals and other key companies, straight to your email.

About Phio Pharmaceuticals

Phio Pharmaceuticals (NASDAQ:PHIO) engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

View Phio Pharmaceuticals Profile

More Earnings Resources from MarketBeat